Dielectrophoretic Separator for Cell/Pathogen Separation

Information

  • Research Project
  • 6585295
  • ApplicationId
    6585295
  • Core Project Number
    R43AI054003
  • Full Project Number
    1R43AI054003-01
  • Serial Number
    54003
  • FOA Number
  • Sub Project Id
  • Project Start Date
    5/15/2003 - 21 years ago
  • Project End Date
    8/14/2004 - 19 years ago
  • Program Officer Name
    SWAIN, AMY L
  • Budget Start Date
    5/15/2003 - 21 years ago
  • Budget End Date
    8/14/2004 - 19 years ago
  • Fiscal Year
    2003
  • Support Year
    1
  • Suffix
  • Award Notice Date
    -
Organizations

Dielectrophoretic Separator for Cell/Pathogen Separation

DESCRIPTION (provided by applicant): The ability to isolate and concentrate rare cells or pathogens is fundamental to numerous biological and medical applications, often forming the starting point for down stream bioassays. Current approaches for cell isolation include centrifugation, filtration, fluorescent- and magnetic-activated cell sorting, and dielectrophoretic (DEP) cell separation. Among them, the DEP separator provides the advantages of speed, flexibility, controllability, and ease of application to automation. However, conventional DEP cell separators, containing two-dimensional (2-D) planar electrode arrays, often cannot process large volumes of samples at a time that is essential for rare cell or pathogen separation. A new three-dimensional (3-D) DEP cell/pathogen separation system is proposed, which is capable of processing large volume of samples with significantly improved collection efficiency. As examples of the relevance of the new system to clinical oncology, infectious disease and biowarfare, human monocytic (U937) and cervic carcinoma (HeLa) cells will be separated from blood, Escherichia coli and Salmonella typhimudum bacteria will be separated from blood, and Bacillus globigii will be concentrated from water. There examples address the needs of lowering the threshold for detection of cancer cells in blood, with the goal of diagnosing infectious disease and biowarfare agents without the need to first culture the pathogens.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R43
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    147503
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    856
  • Ed Inst. Type
  • Funding ICs
    NIAID:147503\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    NANOGEN, INC.
  • Organization Department
  • Organization DUNS
    840610273
  • Organization City
    SAN DIEGO
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    921214340
  • Organization District
    UNITED STATES